About
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Visit company website
5 years, 5 months ago
Avecho Biotechnology Limited is currently in a long term downtrend where the price is trading 13.9% below its 200 day moving average.
From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 73.5.
Avecho Biotechnology Limited's total revenue sank by 0.0% to $31K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-728K since the same quarter in the previous year.
Finally, its free cash flow grew by 56.5% to $-311K since the same quarter in the previous year.
Based on the above factors, Avecho Biotechnology Limited gets an overall score of 2/5.